ALXN1840 has demonstrated a well-characterized and favorable safety profile across Phase 2 and Phase 3 studies (266 patients; median 2.58 years on treatment; max >8 years), with drug-related serious ...
This multimodal MRI study shows that hepatic iron deposition, brain iron accumulation, and selective brain atrophy differ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results